Difficulty: Medium
Average Score: 83%
Practice
What is an appropriate treatment option for HIV patients in the first trimester of pregnancy?
Correct answer
D
Rationale
In the scenario of an HIV-positive patient in the first trimester of pregnancy, the appropriate treatment option is oral AZT (Option D). This choice is based on established guidelines for managing HIV in pregnancy.
Oral AZT is recommended for HIV-infected pregnant women, regardless of gestational age, to decrease the risk of vertical transmission to the fetus. AZT is a proven antiretroviral medication that helps reduce viral load in the mother, thereby lowering the risk of transmission to the unborn child. Starting treatment early in pregnancy, even during the first trimester, is crucial for its effectiveness in preventing mother-to-child transmission of HIV.
Option A, delaying treatment until the 2nd trimester, is not recommended as it increases the risk of transmission during the early stages of pregnancy when crucial fetal development occurs. Option B, using both oral and intravenous AZT, is not typically necessary unless there are specific clinical indications for intravenous administration. Option C, intravenous AZT alone, is not the standard of care for HIV treatment in pregnant women.
Understanding the appropriate management of HIV in pregnancy is vital for nurses providing care to expectant mothers with HIV. By selecting the correct treatment option and understanding why it is the best choice, nurses can actively contribute to improving outcomes for both the mother and the baby. This knowledge ensures that nursing care is evidence-based and aligned with current best practices in family-centered care.
Oral AZT is recommended for HIV-infected pregnant women, regardless of gestational age, to decrease the risk of vertical transmission to the fetus. AZT is a proven antiretroviral medication that helps reduce viral load in the mother, thereby lowering the risk of transmission to the unborn child. Starting treatment early in pregnancy, even during the first trimester, is crucial for its effectiveness in preventing mother-to-child transmission of HIV.
Option A, delaying treatment until the 2nd trimester, is not recommended as it increases the risk of transmission during the early stages of pregnancy when crucial fetal development occurs. Option B, using both oral and intravenous AZT, is not typically necessary unless there are specific clinical indications for intravenous administration. Option C, intravenous AZT alone, is not the standard of care for HIV treatment in pregnant women.
Understanding the appropriate management of HIV in pregnancy is vital for nurses providing care to expectant mothers with HIV. By selecting the correct treatment option and understanding why it is the best choice, nurses can actively contribute to improving outcomes for both the mother and the baby. This knowledge ensures that nursing care is evidence-based and aligned with current best practices in family-centered care.